AstraZeneca’s global biologics R&D arm MedImmune has received fast track designation from the US Food and Drug Administration (FDA) to develop MEDI8897, an investigational recombinant human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb).
This monoclonal antibody is being examined for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children.
{iframe}http://processandproduction.pharmaceutical-business-review.com/news/medimmune-gets-fda-fast-track-status-for-medi8897-to-prevent-lrti-caused-by-rsv-in-infants-100415-4551055{/iframe}